Was your child recently diagnosed with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)? Consider enrolling them in the ProPANS IVIG study.

This study will look at how well an IVIG study drug* may work for children ages 6-17 who have PANS. Other study requirements apply.

*This drug has been FDA approved to address other conditions, but it is not FDA approved for the use of addressing PANS symptoms in children.

Study participants receive at no cost:
- Access to a new IVIG study drug that may help with managing PANS
- All participants will receive the study drug and placebo (no active ingredients). Participants will be randomly assigned to receive the study drug in either the first or second half of the study
- Study support and study-related monitoring by a healthcare team
- Help with study-related travel expenses, including reimbursements for lodging, transportation, and meals
- Education about PANS
- The opportunity to help advance PANS research

The ProPANS study will be conducted at a select number of medical universities and institutions. For more information about enrollment or to find the site nearest you, please contact:

Snehal Udavat
Clinical operations at Octapharma USA, Inc.
201-604-1124
snehal.udavat@octapharma.com